ReviewFrontiers in microbiology2018
Targeting
Review in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Hyperimmune yolk extract with Immunoglobulin Y basic active principle as a possible adjuvant treatment in patients who need/benefit from neurorehabilitation, withJournal of medicine and life · 2022Pooled it
- Article
- Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Immunization of broiler chickens with five newly identified surface-exposed proteins unique to Clostridium perfringens causing necrotic enteritis.Scientific reports · 2023Article
- Non-Toxin-BasedPathogens (Basel, Switzerland) · 2023Article
- Article
- Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance.Chemical reviews · 2022Review
- Curcumin and capsaicin regulate apoptosis and alleviate intestinal inflammation induced by Clostridioides difficile in vitro.Annals of clinical microbiology and antimicrobials · 2022Article
- Investigation of metabolic crosstalk between host and pathogenicFrontiers in bioengineering and biotechnology · 2022Article
- Application of recombinant antibodies for treatment ofFrontiers in immunology · 2022Review
- Immunoinformatics Approach Toward the Introduction of a Novel Multi-Epitope Vaccine AgainstFrontiers in immunology · 2022Article
- Translational Aspects of the Immunology of Clostridioides difficile Infection: Implications for Pediatric Populations.Journal of the Pediatric Infectious Diseases Society · 2021Review
- Comparison of polysaccharide glycoconjugates as candidate vaccines to combat Clostridiodes (Clostridium) difficile.Glycoconjugate journal · 2021Article
- In silico designing of vaccine candidate against Clostridium difficile.Scientific reports · 2021Article
- Identification of linear epitopes on the flagellar proteins of Clostridioides difficile.Scientific reports · 2021Article
- The role of vaccines in combatting antimicrobial resistance.Nature reviews. Microbiology · 2021Review
- What's a Biofilm?-How the Choice of the Biofilm Model Impacts the Protein Inventory ofFrontiers in microbiology · 2021Article
- Host Immune Responses toFrontiers in microbiology · 2021Review
- Homologous Recombination inmSphere · 2020Article
- Detection and elimination of a novel non-toxigenicGut microbes · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New therapies are needed to prevent and treat
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.